Aligos Therapeutics Inc. (ALGS)
Aligos Therapeutics Statistics
Share Statistics
Aligos Therapeutics has 6.11M shares outstanding. The number of shares has increased by -91.85% in one year.
| Shares Outstanding | 6.11M |
| Shares Change (YoY) | -91.85% |
| Shares Change (QoQ) | 76.5% |
| Owned by Institutions (%) | 25.81% |
| Shares Floating | 4.62M |
| Failed to Deliver (FTD) Shares | 86 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 722.35K, so 11.81% of the outstanding shares have been sold short.
| Short Interest | 722.35K |
| Short % of Shares Out | 11.81% |
| Short % of Float | 15.63% |
| Short Ratio (days to cover) | 3.53 |
Valuation Ratios
The PE ratio is -1.9 and the forward PE ratio is -0.4. Aligos Therapeutics's PEG ratio is 0.
| PE Ratio | -1.9 |
| Forward PE | -0.4 |
| PS Ratio | 63.27 |
| Forward PS | 0.1 |
| PB Ratio | -8.61 |
| P/FCF Ratio | -3.09 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Aligos Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.86, with a Debt / Equity ratio of -0.29.
| Current Ratio | 2.86 |
| Quick Ratio | 2.86 |
| Debt / Equity | -0.29 |
| Debt / EBITDA | -0.09 |
| Debt / FCF | -0.1 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $56.36K |
| Profits Per Employee | $-1.87M |
| Employee Count | 70 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 331K |
| Effective Tax Rate | -0.25% |
Stock Price Statistics
The stock price has increased by -77.25% in the last 52 weeks. The beta is 2.72, so Aligos Therapeutics's price volatility has been higher than the market average.
| Beta | 2.72 |
| 52-Week Price Change | -77.25% |
| 50-Day Moving Average | 14.25 |
| 200-Day Moving Average | 17.1 |
| Relative Strength Index (RSI) | 25.97 |
| Average Volume (20 Days) | 214.54K |
Income Statement
In the last 12 months, Aligos Therapeutics had revenue of 3.94M and earned -131.21M in profits. Earnings per share was -20.94.
| Revenue | 3.94M |
| Gross Profit | 3.94M |
| Operating Income | -89.15M |
| Net Income | -131.21M |
| EBITDA | -89.15M |
| EBIT | -89.15M |
| Earnings Per Share (EPS) | -20.94 |
Balance Sheet
The company has 37M in cash and 8.38M in debt, giving a net cash position of 28.62M.
| Cash & Cash Equivalents | 37M |
| Total Debt | 8.38M |
| Net Cash | 28.62M |
| Retained Earnings | -618.01M |
| Total Assets | 70.09M |
| Working Capital | 40.4M |
Cash Flow
In the last 12 months, operating cash flow was -80.74M and capital expenditures -130K, giving a free cash flow of -80.87M.
| Operating Cash Flow | -80.74M |
| Capital Expenditures | -130K |
| Free Cash Flow | -80.87M |
| FCF Per Share | -12.91 |
Margins
Gross margin is 100%, with operating and profit margins of -2259.92% and -3326.01%.
| Gross Margin | 100% |
| Operating Margin | -2259.92% |
| Pretax Margin | -3317.62% |
| Profit Margin | -3326.01% |
| EBITDA Margin | -2259.92% |
| EBIT Margin | -2259.92% |
| FCF Margin | -2050.01% |
Dividends & Yields
ALGS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ALGS is $70, which is 1373.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $70 |
| Price Target Difference | 1373.7% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Aug 19, 2024. It was a backward split with a ratio of 1:25.
| Last Split Date | Aug 19, 2024 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | -15.65 |
| Piotroski F-Score | 3 |